DNA methylation and gene silencing in cancer
- PMID: 16341240
- DOI: 10.1038/ncponc0354
DNA methylation and gene silencing in cancer
Abstract
Epigenetic changes such as DNA methylation act to regulate gene expression in normal mammalian development. However, promoter hypermethylation also plays a major role in cancer through transcriptional silencing of critical growth regulators such as tumor suppressor genes. Other chromatin modifications, such as histone deacetylation and chromatin-binding proteins, affect local chromatin structure and, in concert with DNA methylation, regulate gene transcription. The DNA methylation inhibitors azacitidine and decitabine can induce functional re-expression of aberrantly silenced genes in cancer, causing growth arrest and apoptosis in tumor cells. These agents, along with inhibitors of histone deacetylation, have shown clinical activity in the treatment of certain hematologic malignancies where gene hypermethylation occurs. This review examines alteration in DNA methylation in cancer, effects on gene expression, and implications for the use of hypomethylating agents in the treatment of cancer.
Similar articles
-
Reactivating the expression of methylation silenced genes in human cancer.Oncogene. 2002 Aug 12;21(35):5496-503. doi: 10.1038/sj.onc.1205602. Oncogene. 2002. PMID: 12154410 Review.
-
Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.Ann Hematol. 2005 Dec;84 Suppl 1:54-60. doi: 10.1007/s00277-005-0006-z. Ann Hematol. 2005. PMID: 16228241
-
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.Cancer Res. 2002 Nov 15;62(22):6456-61. Cancer Res. 2002. PMID: 12438235
-
Demethylation of DNA by decitabine in cancer chemotherapy.Expert Rev Anticancer Ther. 2004 Aug;4(4):501-10. doi: 10.1586/14737140.4.4.501. Expert Rev Anticancer Ther. 2004. PMID: 15270655 Review.
-
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.Haematologica. 2002 Dec;87(12):1324-41. Haematologica. 2002. PMID: 12495905 Review.
Cited by
-
Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics.Genome Med. 2013 May 29;5(5):47. doi: 10.1186/gm451. eCollection 2013. Genome Med. 2013. PMID: 23731665 Free PMC article. Review.
-
Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines.Clin Cancer Res. 2013 Jun 15;19(12):3201-11. doi: 10.1158/1078-0432.CCR-12-3751. Epub 2013 Apr 29. Clin Cancer Res. 2013. PMID: 23630167 Free PMC article.
-
Sex-biased expression of the TLR7 gene in severe COVID-19 patients: Insights from transcriptomics and epigenomics.Environ Res. 2022 Dec;215(Pt 2):114288. doi: 10.1016/j.envres.2022.114288. Epub 2022 Sep 21. Environ Res. 2022. PMID: 36152884 Free PMC article.
-
Association of the MTHFR C677T polymorphism with primary brain tumor risk.Tumour Biol. 2013 Dec;34(6):3457-64. doi: 10.1007/s13277-013-0922-9. Epub 2013 Jul 12. Tumour Biol. 2013. PMID: 23846816
-
Retinoid differentiation therapy for common types of acute myeloid leukemia.Leuk Res Treatment. 2012;2012:939021. doi: 10.1155/2012/939021. Epub 2012 Jun 12. Leuk Res Treatment. 2012. PMID: 23213553 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
